Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	31.63	18.53	19.13	19.99	5.74
Cash & Short-Term Investments	31.63	18.53	19.13	19.99	5.74
Cash Growth	70.69%	-3.10%	-4.34%	248.19%	-
Other Current Assets	0.08	0.07	0.06	0.41	0.09
Total Current Assets	31.71	18.61	19.19	20.41	5.83
Long-Term Deferred Charges	-	-	-	-	0.82
Total Assets	31.71	18.61	19.19	20.41	6.66
Accounts Payable	6.27	2.5	2.77	2.91	1.06
Accrued Expenses	7.02	6.4	4.21	2.83	0.54
Other Current Liabilities	-	-	-	0.45	0.82
Total Current Liabilities	13.3	8.89	6.98	6.19	2.42
Total Liabilities	13.3	8.89	6.98	6.19	2.42
Additional Paid-In Capital	118.1	82.96	66.45	46.2	1.89
Retained Earnings	-99.69	-73.25	-54.25	-31.99	-12.9
Total Common Equity	18.41	9.71	12.2	14.22	-11.01
Shareholders' Equity	18.41	9.71	12.2	14.22	4.24
Total Liabilities & Equity	31.71	18.61	19.19	20.41	6.66
Net Cash (Debt)	31.63	18.53	19.13	19.99	5.74
Net Cash Growth	70.69%	-3.10%	-4.34%	248.19%	-
Net Cash Per Share	1.45	1.08	1.23	1.58	1.35
Filing Date Shares Outstanding	26.49	23.39	17.77	14.75	12.72
Total Common Shares Outstanding	25.68	19.5	17.42	14.64	4.51
Working Capital	18.41	9.71	12.2	14.22	3.41
Book Value Per Share	0.72	0.50	0.70	0.97	-2.44
Tangible Book Value	18.41	9.71	12.2	14.22	-11.01
Tangible Book Value Per Share	0.72	0.50	0.70	0.97	-2.44

Updated Feb 11, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q